Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies-Reference-Cited by-同舟云学术

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies

Published:2013-02-06 Issue:8 Volume:27 Page:1628-1636
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

DeAngelo D J,Spencer A,Bhalla K N,Prince H M,Fischer T,Kindler T,Giles F J,Scott J W,Parker K,Liu A,Woo M,Atadja P,Mishra K K,Ottmann O G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201338.pdf

Reference54 articles.

1. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325: 834–840.

2. Bolden JE, Peart MJ, Johnstone RW . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006; 5: 769–784.

3. Minucci S, Pelicci PG . Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38–51.

4. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005; 37: 391–400.

5. StatBite FDA oncology drug product approvals in 2009. J Natl Cancer Inst 2010; 102: 219.

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in dual-targeting inhibitors of HDAC6 for cancer treatment;European Journal of Medicinal Chemistry;2024-09

2. Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia;Cancers;2024-05-26

3. Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectives;Experimental Hematology & Oncology;2024-04-23

4. Therapeutic targeting of angiopoietins in tumor angiogenesis and cancer development;Biochemical and Biophysical Research Communications;2023-12

5. HDAC inhibitors: Promising agents for leukemia treatment;Biochemical and Biophysical Research Communications;2023-11